New partnership to help families travelling abroad for treatment
We’re delighted to let you know that we’re now working with the St George’s Society of New York who will provide a helping hand for families whose children are having therapies such as immunotherapy clinical trials.
Anti-GD2 antibody therapy update, December 2017
In the UK, the first meeting of the National Institute for Health and Care Excellence (NICE) to appraise dinutuximab beta was held on 23rd November in Manchester.
GamesAid donates £69,729 for children with neuroblastoma
We are delighted to announce another significant award from GamesAid – a charity which supports children’s charities in the UK.
Anti-GD2 antibody therapy update, March 2017
Solving Kids’ Cancer has been working since 2015 to ensure continued availability of, and access to, antibody therapy.
Update on our appeal to NICE regarding dinutuximab
Following the announcement that the National Institute of Health and Care Excellence had refused to fund dinutuximab for UK children with neuroblastoma, we lodged an appeal against the decision on Friday July 29th 2016.
New genetic testing for children with neuroblastoma
Scientists at the Institute of Cancer Research and Royal Marsden Hospital have developed a new genetic test that will be given to children with solid tumours in an effort to analyse genetic changes in 81 cancer genes, with funding from Christopher Smile.
Solving Kids' Cancer visit CRUK Clinical Trials Unit
Leona and James from the Solving Kids’ Cancer team visited the CRUK Clinical Trials Unit (CTU) based at the University of Birmingham this month.
Solving Kids' Cancer UK join European movement Unite2Cure
Solving Kids’ Cancer recently joined the European movement Unite2Cure, which is a parent-led network of groups and individuals from across Europe calling for better treatment and improved access to treatment for children and young people with cancer.
Statement on NICE Interim Unituxin Decision
As you may have heard, last week the National Institute for Health and Care Excellence (NICE) released a statement to say they are considering not approving the drug Unituxin (dinutuximab) for high-risk neuroblastoma patients.
